By Counterforce Health Team in Rinvoq (upadacitinib) —

The Requirements Checklist to Get Rinvoq (upadacitinib) Covered by Aetna (CVS Health) in Pennsylvania

Quick Answer: Getting Rinvoq Covered by Aetna in Pennsylvania

To get Rinvoq (upadacitinib) covered by Aetna (CVS Health) in Pennsylvania, you need prior authorization with documented failure of at least one TNF inhibitor for conditions like rheumatoid arthritis. Submit via Aetna's provider portal or fax to 1-866-249-6155. If denied, Pennsylvania's new external review program has a 50% success rate overturning denials—you have 4 months to appeal through the PA Insurance Department.

Table of Contents

  1. Who Should Use This Checklist
  2. Member & Plan Basics
  3. Clinical Criteria Requirements
  4. Coding and Documentation Hygiene
  5. Your Documentation Packet
  6. Submission Mechanics
  7. Specialty Pharmacy Routing
  8. After Submission: What to Track
  9. Denial Prevention Tips
  10. Pennsylvania Appeals Process
  11. Printable Checklist

Who Should Use This Checklist

This guide is for patients with Aetna (CVS Health) insurance in Pennsylvania who need Rinvoq (upadacitinib) for FDA-approved conditions like rheumatoid arthritis, atopic dermatitis, or inflammatory bowel disease. You'll also find this helpful if you're a clinician submitting prior authorizations or appealing denials.

Expected outcome: With proper documentation, most medically appropriate Rinvoq requests get approved. If initially denied, Pennsylvania's external review process has overturned about 50% of appealed cases in its first year.

Member & Plan Basics

Coverage Requirements

  • Active Aetna coverage: Verify your plan includes prescription drug benefits
  • Plan type: Commercial, employer-sponsored, or marketplace plans (Medicaid and Medicare have different processes)
  • Deductible status: High-deductible plans may require meeting your deductible first
  • Authorization needed: Yes, prior authorization is required for all Rinvoq prescriptions

Formulary Position

Rinvoq is typically placed on Tier 5 (preferred specialty) with CVS Caremark, meaning higher copays but preferred status over non-formulary alternatives.

Clinical Criteria Requirements

FDA-Approved Indications

Rinvoq is approved for:

  • Rheumatoid arthritis (moderate to severe)
  • Psoriatic arthritis and ankylosing spondylitis
  • Atopic dermatitis (moderate to severe)
  • Ulcerative colitis and Crohn's disease
  • Non-segmental vitiligo

Step Therapy Requirements

Aetna requires documented failure of:

Condition Required Prior Therapy
Rheumatoid Arthritis At least one TNF inhibitor (adalimumab, etanercept, etc.)
Atopic Dermatitis Topical steroids, other systemic therapies
Crohn's/UC At least one TNF blocker
Psoriatic Arthritis Conventional DMARDs or one biologic

Dosing and Duration

  • Standard dose: 15 mg once daily (most conditions)
  • Atopic dermatitis: 15-30 mg daily in adults
  • IBD induction: 45 mg daily, then 15 mg maintenance
  • Quantity limits: 360 mL every 30 days for oral solution; 30 tablets monthly for standard dosing

Coding and Documentation Hygiene

ICD-10 Codes

Use the most specific diagnosis code:

  • RA: M05.9 (with RF), M06.9 (other)
  • Atopic dermatitis: L20.9 (unspecified), L20.82 (flexural)
  • Crohn's: K50.90 (unspecified)
  • UC: K51.90 (unspecified)
  • Psoriatic arthritis: L40.50-59

HCPCS Coding

  • J3241: Upadacitinib, oral, 1 mg (verify current year's code)

Lab Requirements

Document baseline and monitoring labs:

  • CBC with differential
  • Liver function tests
  • Lipid panel
  • TB screening (chest X-ray, interferon-gamma release assay)

Your Documentation Packet

Provider Note Elements

Your clinician's note should include:

  1. Diagnosis confirmation with severity assessment
  2. Prior therapy history with specific drug names, durations, and outcomes
  3. Current disease activity with objective measures when available
  4. Treatment goals and expected monitoring plan
  5. Risk-benefit assessment addressing FDA boxed warnings

Medical Necessity Letter Components

A strong letter includes:

Template opening: "I am requesting prior authorization for Rinvoq (upadacitinib) for my patient with [diagnosis]. The patient has moderately to severely active disease confirmed by [clinical findings]."

Key sections:

  • Failed therapies: List each prior treatment with duration and reason for discontinuation
  • Clinical rationale: Why Rinvoq is appropriate now
  • Monitoring plan: How you'll track safety and efficacy
  • Guideline support: Reference relevant treatment guidelines

Required Attachments

  • Chart notes supporting diagnosis and severity
  • Lab results (baseline screening)
  • Prior authorization form (completed)
  • Prescription with accurate dosing

Submission Mechanics

Correct Forms and Portals

Common Rejection Causes

Avoid these frequent mistakes:

  • Incomplete prior therapy documentation
  • Missing baseline lab results
  • Incorrect dosing or quantity
  • Unsigned forms or missing provider information
  • Wrong diagnosis codes

Specialty Pharmacy Routing

CVS Specialty Process

Most Aetna plans route Rinvoq through CVS Specialty Pharmacy:

  1. After approval: CVS Specialty contacts patient to coordinate delivery
  2. First fill: Usually ships within 3-5 business days
  3. Ongoing refills: Automated unless dosing changes

Transfer Steps

If switching from another specialty pharmacy:

  • Contact CVS Specialty at the number on your approval letter
  • Provide current prescription and insurance information
  • Confirm delivery address and timing preferences

After Submission: What to Track

Confirmation and Status

  • Reference number: Save your submission confirmation
  • Timeline: Standard decisions within 30-45 days; expedited (urgent) within 72 hours
  • Status checks: Use Aetna's provider portal or call member services

What to Record

Keep a log with:

  • Submission date and method
  • Reference/confirmation numbers
  • Follow-up dates and outcomes
  • Any additional information requested

Denial Prevention Tips

Five Common Pitfalls and Solutions

  1. Insufficient step therapy documentation
    • Fix: Include specific drug names, dates, dosages, and clear reasons for failure
  2. Missing safety screening
    • Fix: Submit complete TB screening and baseline labs with initial request
  3. Unclear medical necessity
    • Fix: Quantify disease severity with validated measures when possible
  4. Incomplete prior authorization forms
    • Fix: Double-check all required fields before submission
  5. Wrong submission route
    • Fix: Verify current PA process—some plans use different vendors
From our advocates: We've seen the strongest approvals include a clear timeline of prior therapies with specific failure reasons. One successful appeal included a simple table showing "Drug X tried 6/2023-12/2023, discontinued due to inadequate response after 6 months at maximum dose." This concrete documentation helped overturn an initial step therapy denial.

Pennsylvania Appeals Process

Internal Appeals with Aetna

If your initial request is denied:

  1. Timeline: You have 180 days to appeal
  2. Method: Submit through Aetna's member portal or by mail
  3. Documentation: Include additional clinical support, peer-reviewed studies, or specialist consultation

External Review Program

Pennsylvania's Independent External Review Program offers a second chance:

  • Eligibility: Must complete Aetna's internal appeals first
  • Timeline: 4 months from final denial to file external review
  • Success rate: Over 50% of appeals are overturned
  • Process: Independent medical reviewers make binding decisions
  • Cost: Free to consumers

When to Escalate

Contact the Pennsylvania Insurance Department if:

  • Aetna doesn't respond within required timeframes
  • You need help with the external review process
  • You suspect improper denial practices

Counterforce Health helps patients and clinicians turn insurance denials into successful appeals by analyzing denial letters, plan policies, and clinical notes to create targeted, evidence-backed rebuttals. The platform identifies specific denial reasons and drafts point-by-point responses aligned with each payer's own rules, significantly improving approval rates for complex cases like specialty medications.

Printable Checklist

Before You Start

  • Verify active Aetna coverage with prescription benefits
  • Confirm FDA-approved diagnosis for Rinvoq
  • Document failed prior therapies with dates and reasons
  • Complete baseline lab screening (CBC, LFTs, TB screen)

Documentation Packet

  • Completed prior authorization form
  • Medical necessity letter with clinical rationale
  • Chart notes supporting diagnosis and severity
  • Lab results and imaging (if applicable)
  • Prior therapy documentation with specific outcomes

Submission

  • Submit via Aetna provider portal or approved fax
  • Save confirmation number and submission date
  • Set calendar reminder for follow-up (30 days)
  • Verify specialty pharmacy routing if approved

If Denied

  • Request detailed denial reason
  • Gather additional supporting documentation
  • Submit internal appeal within 180 days
  • Consider external review if internal appeal fails
  • Contact PA Insurance Department for assistance if needed

FAQ

How long does Aetna prior authorization take in Pennsylvania? Standard decisions take 30-45 days. Expedited requests for urgent medical situations are processed within 72 hours.

What if Rinvoq isn't on my formulary? You can request a formulary exception with documentation showing medical necessity and failure of preferred alternatives.

Can I get help with the appeals process? Yes, Pennsylvania offers free consumer assistance through the Health Law Project and the Insurance Department's consumer services.

Does step therapy apply if I failed treatments in another state? Yes, prior therapy failures from other states count toward step therapy requirements if properly documented.

What's the cost difference between tiers? Tier 5 specialty drugs typically have the highest copays or coinsurance, often $100-500+ per month depending on your specific plan.

Sources & Further Reading

This information is for educational purposes only and doesn't constitute medical advice. Always consult your healthcare provider about treatment decisions and work with them on insurance authorizations. For personalized assistance with Pennsylvania insurance appeals, contact the PA Insurance Department consumer services line.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.